Streptococcus Salivarius: Pathogenesis, Immunity, Resistance

Streptococcus salivarius is one of the first bacteria to colonize the human mouth after birth and remains a dominant member of the oral and upper respiratory microbiome throughout life. Far from being a passive bystander, it actively shapes its environment by producing antimicrobial peptides, dampening inflammatory signaling, and competing with genuine pathogens for space. Yet this mostly benign organism has a darker side: it can cause serious bloodstream infections when it breaches damaged mucosal barriers, and it harbors mobile genetic elements capable of spreading antibiotic resistance to neighboring species.

An Early Arrival That Stays for Life

Within the first month of life, S. salivarius is already among the most abundant streptococci in an infant’s mouth. A study of 367 pioneer streptococcal strains isolated from 40 healthy newborns found that S. salivarius made up about a quarter of all isolates, trailing only the combined share of S. mitis biovar 1 and S. oralis.¹ Its favored niche is the tongue dorsum and the soft tissues of the cheek and palate, though it also persists further down the digestive tract. Genomic studies of strains collected from saliva, gut contents, breast milk, and even blood have not turned up clear genetic signatures that distinguish strains from one body site versus another, suggesting a generalist lifestyle rather than tight niche specialization.²

How It Sticks Around

Colonizing an environment as turbulent as the mouth requires a toolkit of adhesins. S. salivarius expresses at least three large, glycosylated serine-rich repeat proteins, designated SrpA, SrpB, and SrpC, that are secreted through a specialized transport system and displayed on the cell surface. SrpB and SrpC play complementary roles: they promote auto-aggregation (cells clumping together), biofilm formation, and attachment to epithelial cells and host molecules. Together, these three proteins are considered the main drivers of S. salivarius colonization.³

Beyond these serine-rich proteins, genome sequencing of the well-characterized strain F6-1 identified 36 genes encoding potential surface proteins. When researchers knocked out six of them individually and tested the mutants for adhesion to intestinal epithelial cells, four turned out to be genuine adhesins involved in host-cell binding.⁴ The fact that S. salivarius can adhere to both oral and gut epithelium reinforces its generalist image and helps explain why it sometimes turns up in probiotic formulations aimed at the digestive tract, not just the mouth.

Salivaricins and the War Against Competitors

One of S. salivarius’s most studied features is its ability to produce bacteriocin-like inhibitory substances, or BLIS. These are small antimicrobial peptides that kill or inhibit closely related bacteria. The probiotic strain K12, for instance, carries a large plasmid that encodes two lantibiotics called salivaricin A and salivaricin B.⁵ Lantibiotics are a class of peptides that contain unusual amino acid structures, giving them a rigid ring shape that punches holes in the membranes of susceptible bacteria. Additional salivaricins have since been described, including salivaricin D, a 34-amino-acid peptide discovered in a strain isolated from a healthy infant. The gene cluster encoding salivaricin D also contains its own immunity gene, which, when transferred into a sensitive strain, protected it from killing. That self-immunity mechanism ensures S. salivarius does not destroy itself with its own weapon.⁶

The antimicrobial reach of salivaricins extends to several clinically relevant targets, including Streptococcus pyogenes (the cause of strep throat) and other oral pathogens. Research into these molecules is ongoing, with interest in whether they could eventually be purified and used as stand-alone therapeutics rather than delivered via live bacteria.⁷

Competing With Cavity-Causing Bacteria in Biofilms

Dental plaque is a biofilm, and which species dominate that biofilm has real consequences for tooth decay. Streptococcus mutans is one of the chief villains in cavity formation because it produces large amounts of acid and sticky polysaccharides from sugar. S. salivarius appears to push back against S. mutans through at least two mechanisms.

First, when S. salivarius K12 is present during the early stages of biofilm development, it reduces the proportion of S. mutans, disrupting the three-dimensional architecture of the biofilm and inhibiting pathogen-dominated microcolony formation.⁸ In laboratory biofilm models using salivary bacteria mixed with S. mutans, adding high concentrations of K12 cut the total biofilm biomass by roughly a third compared to untreated controls and significantly reduced S. mutans counts while increasing S. salivarius counts.⁹

Second, S. salivarius produces an enzyme called fructanase (FruA) in large quantities. Purified FruA completely blocked S. mutans biofilm formation on saliva-coated surfaces, not by breaking down fructan polymers as you might expect, but by decreasing the polysaccharide production that S. mutans depends on when metabolizing sucrose.¹⁰ So S. salivarius is not merely elbowing out S. mutans for space; it is actively dismantling the molecular scaffold S. mutans uses to build its biofilm.

Calming Inflammation From the Inside

Beyond competing with pathogens, S. salivarius appears to dial down the host’s inflammatory machinery. In cell-culture experiments, supernatants from multiple S. salivarius strains suppressed activation of the NF-κB signaling pathway in intestinal epithelial cells after those cells were stimulated with tumor necrosis factor alpha (TNF-α). The two most potent strains produced a small metabolite, under 3 kilodaltons in size, that lowered secretion of the pro-inflammatory chemokine interleukin-8.¹¹ Follow-up work confirmed that live S. salivarius strains inhibited NF-κB activation in the same intestinal cell models.¹²

This anti-inflammatory activity has attracted clinical interest. In one study exploring oral lichen planus, a chronic inflammatory condition of the mouth, supernatants from a reference S. salivarius strain significantly reduced expression of interleukin-6 in oral squamous cells, and other inflammatory markers trended downward as well. The researchers proposed that S. salivarius helps maintain local immune balance through NF-κB suppression.¹³ If the oral mucosa is thought of as a neighborhood, S. salivarius seems to function less like a security guard and more like a mediator that keeps the immune system from overreacting to the constant flow of microbial traffic.

Probiotic Trials and Their Mixed Results

The combination of antimicrobial peptides and anti-inflammatory signaling has made S. salivarius K12 a popular candidate for probiotic lozenges and sprays. Some early clinical results were striking. In one open-label trial of 30 children given a K12-based product called Bactoblis for 90 days, the incidence of streptococcal throat infections dropped by roughly 96% compared to the same children’s infection rates the previous year.¹⁴ Another trial following over 200 kindergartners for six months reported that children receiving daily K12 had markedly lower rates of streptococcal pharyngitis and ear infections compared to untreated controls.¹⁵

Those results sound impressive, but the studies were small and unblinded or minimally blinded. When a much larger randomized, placebo-controlled trial tested K12 lozenges specifically for preventing acute otitis media in over 800 children, the probiotic did not outperform placebo. About 8% of children in the K12 group and 6% in the placebo group experienced at least one ear infection episode over six months, and the time to the first episode was virtually identical between groups.¹⁶ The gap between the early enthusiasm and this large negative trial is a familiar pattern in probiotics research: promising open-label findings that do not survive rigorous testing. That does not mean S. salivarius probiotics are useless, but it does mean we do not yet have strong evidence that they prevent ear infections in children.

A preliminary study in hospitalized COVID-19 patients explored whether K12 supplementation could influence inflammatory markers and outcomes. The researchers reported improvements in blood markers of inflammation and higher survival in the treated group, but the study was small and preliminary, and the findings need confirmation in larger trials before drawing practical conclusions.¹⁷

Safety, at least, does not appear to be a major concern for the probiotic strains. Both K12 and M18 (a strain marketed more for dental health) are recognized as non-pathogenic commensals, and their safety profile has been validated in early research, including in children.¹⁸

When a Commensal Turns Dangerous

Despite its generally harmless reputation, S. salivarius can cause life-threatening infections when the usual barriers fail. A prospective 16-year study found that S. salivarius bloodstream infections occurred predominantly in patients with significant disruption of the mucous membranes or serious underlying diseases.¹⁹ Dental procedures, chemotherapy-induced mouth sores, and gastrointestinal surgery are common entry points.

Case reports illustrate how severe these infections can become. One elderly patient with no known immune deficiency developed S. salivarius bacteremia complicated by both bacterial meningitis and infective endocarditis after a routine dental cleaning. Imaging revealed vegetation on the mitral valve with moderate regurgitation.²⁰ In another case, an autopsy revealed S. salivarius endocarditis involving both the mitral and aortic valves, with infarcts in the kidney and spleen from embolic debris, in a patient whose cause of death had initially been unclear.²¹

These cases are rare, and they should not overshadow the fact that the vast majority of people carry S. salivarius without incident. But they underscore a theme in microbiology: a bacterium’s status as “commensal” is situational, not absolute. When the mucosal barrier is breached and the organism reaches sterile sites like the bloodstream or the heart valves, even a friendly resident can behave like a pathogen.

Antibiotic Resistance and the Genes Behind It

Treating S. salivarius infections when they do occur is complicated by rising antibiotic resistance. An older study from Taiwan found that while high-level penicillin resistance was less common in S. salivarius (about 8% of isolates) than in species like S. oralis (35%) or S. mitis (20%), only half of S. salivarius isolates were fully susceptible to penicillin. Resistance rates also varied for macrolides and tetracycline.²² A more recent decade-long survey of viridans group streptococci in the United States confirmed that penicillin susceptibility varies considerably by species, with S. mitis showing lower susceptibility than some of its relatives.²³

Genetic analysis of both clinical and commensal S. salivarius isolates has revealed high rates of erythromycin and tetracycline resistance. The mechanisms differ depending on the source. Clinical strains tend to carry either the erm(B) gene, which confers broad resistance to macrolides, lincosamides, and streptogramin B antibiotics, or the mef(A/E) efflux pump gene. Commensal strains almost universally carry the mef(A/E) gene housed on a mobile genetic assembly called MEGA.²⁴ The distinction matters because erm(B) typically produces stronger resistance than the efflux-based mechanism, which means clinical isolates may be harder to treat than what you would predict from surveillance of healthy mouths.

Sharing Resistance Genes With Neighbors

Perhaps the most consequential aspect of S. salivarius resistance is how it spreads. Whole-genome sequencing has identified at least 13 integrative and conjugative elements (ICEs) in various S. salivarius strains. These are chunks of chromosomal DNA that can excise themselves, form a ring, and transfer to a new bacterial cell during conjugation. Some of these ICEs carry cargo genes for bacteriocin production or heavy-metal resistance alongside antibiotic resistance determinants. When researchers tested whether two of these elements could actually transfer, they found they moved not only to other S. salivarius strains but also to the dairy bacterium Streptococcus thermophilus and to the hospital-associated pathogen Enterococcus faecalis.²⁵ Closely related elements have been detected in silico in S. pneumoniae and S. parasanguinis, suggesting that this genetic highway runs through multiple species sharing the oral and digestive tracts.

For clinicians, the takeaway is that S. salivarius is not just a potential low-level pathogen in its own right. It can also function as a reservoir, accumulating resistance genes through antibiotic exposure and then donating them to species that cause far more disease. Each course of antibiotics a person takes applies selective pressure to the vast commensal population in the mouth and gut, potentially enriching for resistant S. salivarius clones that then pass those genes along.

Identifying S. salivarius in the Lab

Getting the species-level identification right matters for both clinical management and research. Among the viridans group streptococci, S. salivarius can be tricky to distinguish from close relatives using traditional biochemical tests or even some molecular techniques. MALDI-TOF mass spectrometry, which identifies bacteria by their protein fingerprint, has emerged as the most practical tool. In one evaluation, the direct-colony method correctly identified all S. salivarius isolates at the species level.²⁶ A separate multi-instrument comparison found that while molecular sequencing often could not distinguish among the salivarius-group streptococci, MALDI analysis achieved fast, reliable classification and was the most practical option for routine lab use.²⁷

Accurate identification is especially relevant when S. salivarius turns up in blood cultures. Because viridans streptococci are common contaminants, a blood culture growing “viridans strep” might be dismissed. Species-level identification helps clinicians decide whether the isolate is likely a true pathogen (as in the endocarditis cases described above) or a skin contaminant introduced during the blood draw.

The Dairy Connection

Readers who have encountered “Streptococcus thermophilus” on a yogurt label may wonder how it relates to S. salivarius. S. thermophilus is classified as a subspecies of S. salivarius: formally, Streptococcus salivarius subsp. thermophilus. While it shares a close evolutionary ancestor with the oral strains, millennia of adaptation to milk environments have given it a narrowed genome and distinct metabolic profile. It is used alongside Lactobacillus delbrueckii subsp. bulgaricus as a starter culture for yogurt production, where its acid production and flavor-compound generation are essential to the final product.²⁸ The fact that one subspecies lives on the human tongue and the other thrives in heated milk is a vivid example of how closely related bacteria can diverge dramatically in their ecology while remaining genetically intertwined. It also means that horizontal gene transfer between S. salivarius and S. thermophilus, as demonstrated with ICEs in the lab, is not purely an academic curiosity. Dairy streptococci and oral streptococci do occasionally meet in the human digestive tract, and the genetic exchange observed in vitro could have real-world consequences for the spread of resistance determinants across food and clinical microbiology.